The New Age of Alzheimer’s Disease
A new age for Alzheimer’s disease (AD) stands before us, with unprecedented possibilities for patients, care partners, and health care professionals. Paired with our long-term vision and commitment to our human health care (hhc) mission, we use deep human biology and genetic evidence with the goal of providing the right intervention, for the right person, at the right time.
What Is Alzheimer’s Disease?
Alzheimer’s disease (AD) is progressive. Even in the early stages, AD can begin to interfere with daily life.
AD is linked to the build-up of amyloid protein in the brain, which over time can damage brain cells and clump together into harmful amyloid brain plaques.
Various mechanisms have been proposed over the years to describe the pathogenic events that lead to the development of AD, all of which suggest that the presence of Aβ and tau, synaptic failure, and neuronal dysfunction are common features of AD and play a pivotal role in cognitive dysfunction.
Learn more about the progression of AD
What Does Alzheimer’s Look Like?
There are many complexities in the AD landscape: risk factors, early symptoms, causes, diagnoses, and stages. Early detection is one of the keys to the right person, receiving the right medication, at the right time.
The Key To Our Progress In Two Words? Research Excellence.
When it comes to understanding the science of memory, no detail is too small. To learn more, watch our LinkedIn Live stream on the real-world implications of study design methods and data evaluation in Alzheimer’s disease clinical research.
Unlocking Alzheimer’s: Understanding the Science
Experts Dung Trinh, MD, and Darren Gitelman, MD, joined Eisai’s Susan De Santi, PhD, for a LinkedIn Live event where they discussed numerous aspects of Alzheimer’s disease (AD), including mechanism of disease, blood-based biomarkers, the role of protofibrils in AD progression and evaluating clinical data in AD.
Assessing Meaningful Benefits in Early Alzheimer's Disease (AD)
Click on the video on the right to hear expert discussions on assessing meaningful benefits in early AD using a holistic approach that incorporates multiple stakeholder perspectives: view full series here
Patient-Centered Care Framework in Alzheimer's Disease (AD)
Click on the video on the right to hear experts discuss the urgent need for a patient-centered framework in AD to ensure a timely diagnosis and appropriate patient identification. The time is now: view full series here
Learn About The Underlying Mechanism Of Alzheimer’s Disease
Research has shown that protofibrils play a key role in the neurodegenerative process of Alzheimer’s disease (AD) pathophysiology. Expert neurologists Dennis Selkoe, MD, and Arif Dalvi, MD, joined Eisai’s Michael Irizarry, MD, MPH, to discuss where protofibrils fit in the amyloid-beta pathway and how their neurotoxic effects contribute to AD progression.
Dig Deeper: Resources For HCPs
Our Products